Hypothesis

Age‑associated thiol oxidation drives aberrant liquid‑liquid phase separation that hardens into toxic amyloid fibrils because the disaggregation machinery declines. We propose that the oxidation‑sensitive chaperone Hsp33, when activated by sulfenic/sulfinic modifications on its cysteines, binds exposed hydrophobic patches on misfolded proteins and nucleates amyloid‑like aggregates that remain reversible and non‑toxic. In this view, Hsp33 does not merely prevent aggregation; it actively channels the proteostatic response toward a controlled, functional amyloid state that can be later dissolved by the Hsp110 system. When Hsp33 activity is boosted, the balance shifts from pathological fibrils back to protective, disaggregatable aggregates even in aged cells.

Mechanistic Reasoning

1. Redox sensing – Hsp33 contains tandem cysteine motifs that form disulfide bonds upon oxidation, converting it from a dimeric reductase to a stable holdase/chaperone (see redox‑dependent structural studies).
2. Substrate capture – Oxidized Hsp33 preferentially binds partially unfolded, thiol‑oxidized client proteins, increasing their local concentration.
3. Amyloid templating – The chaperone’s extended surface promotes β‑sheet stacking, nucleating fibrils that retain a loose, hydrated core amenable to Hsp110‑mediated disaggregation (consistent with LLPS‑derived amyloid states described in [2] and [4]).
4. Kinetic competition – By accelerating the formation of reversible aggregates, Hsp33 outruns the oxidative drift toward irreversible sulfonylation‑driven LLPS highlighted in [4]. The resulting aggregates are cleared by the residual disaggregase pool, extending the window of proteostasis.

Testable Predictions

• Prediction 1: Overexpression of wild‑type Hsp33 (but not a cysteine‑mutant that cannot oxidize) in aged C. elegans will increase the proportion of Thioflavin‑positive aggregates that are sensitive to SDS‑solubilization after Hsp110 co‑overexpression.
• Prediction 2: In primary neurons from aged mice, pharmacological activation of Hsp33 (e.g., with diamide at sub‑toxic doses) will reduce insoluble tau and α‑synuclein species while increasing soluble oligomer levels detectable by native PAGE.
• Prediction 3: Genetic knock‑down of Hsp33 will exacerbate sulfonylation‑dependent aggregate hardness (measured by FTIR β‑sheet peak shift) and shorten lifespan under paraquat stress, an effect rescued by Hsp110 overexpression.

Experimental Approach

• Model systems: Use C. elegans strains expressing Aβ1‑42 or τ::YFP under a pan‑neuronal promoter; treat young (day 1) and old (day 10) adults with Hsp33‑inducing plasmids or small‑molecule activators.
• Readouts:
  • Filter‑trap assay for insoluble aggregates.
  • Solubility fractionation followed by western blot for client proteins.
  • Electron microscopy to distinguish amorphous granules from mature fibrils.
  • Lifespan and motility assays.
  • For mammalian validation: primary cortical neurons from 24‑month‑old mice, AAV‑mediated Hsp33 or Cys‑mutant expression, assess phosphorylated tau, synaptic markers, and electrophysiology.
• Controls: Include Hsp33 Cys→Ser mutant (oxidation‑dead) and Hsp110 knock‑down to test reversibility.

Expected Outcomes

If Hsp33 redirects oxidation‑prone misfolded proteins into reversible amyloids, we expect:

• A significant increase in SDS‑soluble, ThT‑positive aggregates in Hsp33‑overexpressing aged animals, correlating with improved stress resistance and lifespan.
• Reduction in cytotoxic, protease‑resistant fibrils concomitant with rise in Hsp110‑dependent disaggregation activity.
• No benefit (or worsening) when the redox‑sensitive cysteines are blocked, confirming the mechanistic link.

Implications

This hypothesis reframes protein aggregation not as a binary garbage‑versus‑toxic switch but as a tunable output of the proteostasis network, where redox‑controlled chaperones dictate aggregate material properties. Therapeutically, enhancing Hsp33’s oxidative activation—alone or in combination with disaggregase upregulation—could restore the protective aggregation pathway that becomes skewed in neurodegeneration and aging.